Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical
Emanuela Dell’Aquila, Lorenzo Antonuzzo, Stefano Tamberi, Daniele Spada et al.
Citations
6 citations
Journal
BMC Cancer
Topics
Gastric Cancer Management and Outcomes
Field-Weighted Citation Impact (FWCI)
9.11
article
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical
Emanuela Dell’Aquila, Lorenzo Antonuzzo, Stefano Tamberi, Daniele Spada, Alessandra Raimondi, Emiliano Tamburini, Andrea Spallanzani, Antonia Strippoli, Francesca Bergamo, Alberto Puccini, Lorenzo Fornaro, Federica Palermo, Federica Morano, Katia Bencardino, Salvatore Corallo, Vincenzo Nasca, Luisa Foltran, Samantha Di Donato, Filippo Pietrantonio, Chiara Alessandra Cella, Antonio Avallone, Oronzo Brunetti
article en
6 citations
Abstract
No abstract available for this paper.
Publication Tag
BMC CancerVol. 25(1)
Institutions
University of Modena and Reggio Emilia (IT), Humanitas University (IT), University of Pavia (IT), Cardinal Health (Australia) (AU), Agostino Gemelli University Polyclinic (IT), Ospedale "Santa Maria delle Croci" di Ravenna (IT), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Istituto Oncologico Veneto (IT), Azienda Ospedaliero-Universitaria Careggi (IT), National Cancer Institute (UA), Centro di Riferimento Oncologico (IT), Istituto Tumori Bari (IT), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Policlinico San Matteo Fondazione (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Ospedale di Prato Santo Stefano (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), IRCCS Humanitas Research Hospital (IT), Azienda Ospedaliera Universitaria Pisana (IT), Istituti Ospitalieri di Cremona (IT), Instituto Nazionale Tumori Regina Elena (IT), Azienda Socio Sanitaria Territoriale di Cremona, University of Florence (IT), European Institute of Oncology (IT)